CCI Closes Case Against Max Patparganj Hospital, Finds DG's Excessive Pricing Analysis Unsustainable

The Competition Commission of India closed a decade-long inquiry against Max Super Specialty Hospital, Patparganj, finding the Director General's methodology for establishing unfair pricing under Section 4 legally insufficient.

The Competition Commission of India, in an order dated 21 May 2026, closed Case No. 77(1) of 2015 against Max Super Specialty Hospital, Patparganj, Delhi. The Commission found that the Director General's supplementary investigation report did not satisfy either limb of the two-stage test for establishing abusive pricing under Section 4(2)(a)(ii) of the Competition Act, 2002. The inquiry, which began in 2015 on a complaint about inflated syringe prices, had expanded over a decade into a wide-ranging examination of room rents, medical tests, consumables, medicines, and medical devices charged to admitted patients across twelve Delhi super-specialty hospitals. The present order, one of twelve sub-case orders, concerns Max Patparganj alone.

How a Syringe Complaint Became a Twelve-Hospital Inquiry

Shri Vivek Sharma filed the original information in 2015 under Section 19(1)(a) of the Act, alleging that Becton Dickinson India (P) Ltd., a disposable syringe manufacturer, had colluded with Max Patparganj to print a higher Maximum Retail Price on syringes sold at the hospital's in-house pharmacy compared with the same product sold in the open market. The Commission formed a prima facie view of contravention of Section 4 and directed the Director General to investigate under Section 26(1).

The DG's first investigation report, considered by the Commission in 2017 and 2018, cleared Becton Dickinson and Max Patparganj of any Section 3(3) cartel violation. There was no exclusive supply agreement between the two entities. However, the DG found that Max Patparganj was dominant in a relevant market defined as provision of healthcare services by private super-specialty hospitals within about 12 kilometres of the hospital, and that it had abused that dominance by compelling in-patients to buy from its in-house pharmacy at high margins.

The Commission, in its order of 31 August 2018, observed that the DG had referred to the conduct as “akin to aftermarket abuse” without analysing it in depth. It directed a supplementary investigation, asking the DG to revisit the relevant market definition using the aftermarket concept, broaden the scope to all aftermarket healthcare products and services across Delhi super-specialty hospitals, and focus particularly on products for which patients had time and scope to exercise rational choice.

The Supplementary Investigation and Its Scope

The DG submitted the supplementary investigation report in December 2021. It covered twelve super-specialty hospitals in Delhi, framing five issues: whether each hospital was an enterprise under Section 2(h); the relevant market; dominance; contravention of Section 4; and individual liability under Section 48.

On relevant market, the DG defined twelve separate markets, one per hospital, as the “market for provision of healthcare services/facilities for in-patients admitted to the respective private super specialty hospital” in Delhi. The rationale was that eleven of the twelve hospitals did not permit patients to purchase consumables, medicines, or medical tests from outside, making each hospital self-contained and independent. Each hospital was therefore found dominant in its own market.

On contravention, the DG found all twelve hospitals in breach of Section 4 between 2015 and 2018 across five parameters: room rent (compared with nearby three-star and four-star hotels); medical tests (compared with four standalone diagnostic laboratories); medical devices including stents, knee implants, and hip implants; consumables (comparing procurement price with selling price); and medicines (same methodology).

Becton Dickinson was deleted from the array of opposite parties in January 2022, as no contravention had been found against it. The eleven other hospitals were impleaded. The Commission directed the DG to prepare twelve separate non-confidential reports, one per hospital, with data of other hospitals redacted, and declared that the matter would be treated as twelve separate sub-cases with separate hearings.

After further procedural steps, including revised unredacted reports submitted in September 2024 and oral hearings held in August, September, and October 2025, the Commission passed the present order on 21 May 2026.

Max Patparganj's Case: Aftermarket Does Not Exist Here

Max Patparganj contested the findings on multiple grounds. On relevant market, it argued that patients come to a hospital for a healthcare service, not for individual goods such as medicines or consumables, and that the DG had wrongly disaggregated a unified service into standalone product markets. Hospitals cannot be substituted with hotels for room rent purposes, or with diagnostic laboratories for medical tests, because they operate in entirely different markets with different cost structures.

On aftermarket, the hospital submitted that an aftermarket exists only where customers cannot estimate life-cycle costs and where reputation effects do not deter supra-competitive pricing. It argued that patients seeking elective treatment are given a detailed cost estimate before admission, covering procedure charges, drugs, consumables, and room rent. Patients are free to reject the estimate, seek a second opinion, or go to another hospital. Several patients do not proceed after receiving the estimate. There is no lock-in. Relying on Shamsher Kataria v. Honda Siel and Ors., the hospital argued that where a customer can switch to a competing primary product, no separate aftermarket arises.

On pricing methodology, the hospital contended that the DG had not applied the two-stage test from United Brands v. Commission of the European Communities, which requires a finding that the price is both excessive and unfair. Excessiveness alone does not establish a Section 4(2)(a)(ii) violation. The DG had compared hospital prices with standalone diagnostic labs and hotels without accounting for the hospital's 24-hour operational requirements, faster turnaround times, and higher quality standards. On consumables and medicines, the hospital pointed out that all items were sold within the MRP fixed by manufacturers, and that no law requires a hospital to pass on procurement-side profits to patients.

The hospital also raised a constitutional point: regulation of pricing in hospitals falls within the exclusive domain of state governments under List II of the Seventh Schedule. It cited the Supreme Court's judgment dated 4 March 2025 in Siddharth Dalmia and Another v. Union of India and Others, where the Court noted that the issue primarily involves policy decisions for which policy-makers are best equipped, and declined to express any opinion on the merits.

How the Commission Analysed the Aftermarket Question

The Commission accepted that Max Patparganj is an enterprise under Section 2(h), being engaged in providing healthcare services in exchange for monetary consideration. It then turned to the central question: whether the market for in-patient healthcare services and the market for medicines, consumables, medical tests, and room rent within the hospital constitute two separate relevant markets (primary and aftermarket) or a single unified systems market.

The Commission identified three conditions relevant to the existence of a separate aftermarket: customers do not engage in whole-life costing; reputation effects do not deter the provider from setting supra-competitive prices in the secondary product; and the cost of switching from the primary product is high enough to create a lock-in.

On the facts, the Commission noted that patients opting for elective treatment typically ascertain the cost of the procedure and associated expenses before admission. The OP provides a detailed cost estimate before any commitment is made. Patients retain the freedom to accept or reject the estimate, seek a second opinion, or choose another hospital. The Commission found, from the documents submitted by the hospital, that the estimates do provide a breakdown of charges across procedure, drugs, consumables, and room rent. This pointed against the existence of a separate aftermarket in the elective treatment context.

Findings on Each Pricing Parameter

On room rent, the Commission found the DG's comparison with nearby three-star and four-star hotels methodologically flawed. Hospital rooms are equipped with automatic patient beds, trained medical staff, and emergency response mechanisms, none of which are present in hotel accommodation. The Commission held that the comparison was not appropriate and the finding of unfair pricing on room rent was not sustainable.

On medical tests, the DG had compared prices for thirteen routine tests with four diagnostic laboratories. The Commission found that the comparison with only one standalone laboratory each for X-ray, MRI, and ultrasound was inadequate. Charges levied by the hospital for certain procedures would qualify as unfair only where they are significantly higher than those charged by other hospitals for comparable services — a comparison the DG did not make. The finding on medical tests was not sustained.

On medical devices, the DG had found an increasing price trend for stents, knee implants, hip implants, and related procedures between 2015 and 2018. The Commission found the DG's finding on unfair pricing for medical devices similarly unsustainable for comparable methodological reasons.

On consumables and medicines, the DG compared procurement prices with selling prices to calculate profit margins. The Commission held this methodology inappropriate: procurement price does not cover overhead expenses including storage, supply chain management, operational costs, and inventory management. The correct comparison would be with prices charged by other super-specialty hospitals or at least nearby pharmacies. The Commission also noted that there was no finding in the supplementary investigation report that any consumable or medicine was sold above the MRP fixed by the manufacturer, that no law requires a hospital to pass on procurement-side profits to patients, and that the sample size taken by the DG was quite limited. The finding on consumables and medicines was not established.

The United Brands Test and the Commission's Conclusion

The Commission applied the two-stage United Brands test: first, whether the price charged bears no reasonable relation to the economic value of the product (the excessive limb); second, whether the price is unfair in itself or when compared to competing products (the unfair limb). It concluded that neither limb was established on any count from the evidence gathered by the DG in the supplementary investigation.

The Commission held that no case of abuse of dominant position in contravention of Section 4 of the Act could be made out against Max Patparganj on the material and evidence available on record.

Order

The Commission directed that Case No. 77(1) of 2015 be closed. All pending interlocutory applications, including IA No. 390 of 2025 filed by the hospital seeking an extension to file written arguments, stand disposed of.

On confidentiality, the Commission granted confidential treatment to documents, data, and information filed by the parties under Regulation 35 of the General Regulations, 2009 (as amended), in terms of Regulation 36 of the General Regulations 2024, read with Section 57 of the Act, for a period of three years from the date of the order. The Commission clarified that nothing disclosed in the order itself is to be treated as confidential, as it has been used and disclosed for the purposes of the Act.

The Secretary was directed to communicate a certified copy of the order to the Informant and the Opposite Party.